Wolf
How about this:
Let's take into account your:
It's possible to break that number down further given the
50% growth that the opined 6300 represented. That would
be 42. I mean 4200
It simply means less 2003 fiscal Pennsaid revenue from Canada and more Pennsaid scripts in Q1 2004 or 13,537 scripts.
I disagree with the 13,000+ answers.
* - this is the same methodology being used here and on SH.
How would you then calculate Q1 scripts?
Now to the "Puzzle":
2003 OXO annual Rev contribution = $316,000 usd
Cumm 9mo 2003 European sales = $35,000 usd
Therefore
Q4 European sales component = $281,000 usd
($281,000 usd = $316,000 - $35,000)
This assumes no European Pennsaid sales in 2003 up to this point, but takes care of the entire OXO contribution.
Italian Pennsaid has to be European Rev.
Q4 2003 Rev = $658,000 usd
Less Q4 OXO Rev of $281,000 usd
Less Q4 Cdn Pennsaid Rev of $77,000 usd
Equals Q4 European Pennsaid Rev of $300,000 usd
(using the 2,800 scripts x $38 = $106,400 cdn
divided by 1.38 = about $77,000 usd)
In my calculations, I do not have any non-Italian European Pennsiad sales. Therefore I can conclude maximum Italian Pennsaid sale is $300,000 usd at the very top end.
If I allow for non-Italian European Pennsaid sales, then I denote this as $uk usd. $uk cannot be larger than $300,000 usd, the cap.
Then Italian Pennsaid sales = $300,000 usd - $uk usd
Have a good evening. |
